THMO Stock : ThermoGenesis Holdings, Inc. (NASDAQ ThermoGenesis Holdings Inc. (NASDAQ) (the “Company”) is a leader in automated processing of cells and point-of care, autologous cells-based therapies, today announced that it received notice from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is now in conformity with Nasdaq’s minimum bid price to continue trading on Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2) (“Min Bid Price Rule”).
On March 7, 2022 Nasdaq informed it was notifying the Company it had was unable to maintain a minimum bid of $1.00 during the preceding 30 consecutive business days , as is required under the Listing Rules of The Nasdaq Stock Market.
On the 9th of January 2023 Nasdaq found that over the past 10 , consecutive days of trading from the 22nd of December, 2022 through January 6 2023 the closing bid of the Company’s common stock been $1.00 for each share, or higher. The Company, therefore, has been able to regain the compliance of Listing Rule 5550(a)(2) and believes that the matter is closed.
Information About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. creates, commercializes and sells a variety of automated CAR-T technologies and other treatments based on cell therapy. The company currently offers the full range of products for automated clinical biobanking, point of care applications, and automated immuno-oncology. Its products include its semi-automated, functionally-closed CAR-TXpress(tm) platform that simplifies the manufacturing process for the burgeoning CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.
Forward-Looking Statements
This press release includes “forward-looking statements” in the sense of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be subject to uncertainties and risks which could cause the actual results to be different from those expressed in the forward-looking statements in this release. When they are used in this press release these phrases “anticipate,” “believe,” “estimate,” “expect” and similar expressions when they pertain to the Company or its management, are intended to indicate forward-looking statements. Actual results, performance or accomplishments could be different from those stated and implied in these forward-looking assertions. The reader should be aware of the important elements that, in certain circumstances, may have caused or in the near future may cause the actual results and performance to be different from the results stated in any forward-looking statements issued on behalf of or by the Company. These include, without limitation the possibility of obtaining the capital or other financing in the quantities and in the timeframes necessary to introduce new products, the market acceptance for new product launches, type and timing of approvals from regulatory authorities for both new and existing products that the Company makes claims for new products realizing forecasted revenue, expenses and earnings initiatives from competitors pricing pressures, the failure to comply with FDA regulations governing the operation of the Company’s products (including the possibility of recalls of products resulting from these regulations) and the risks involved in the process of establishing manufacturing for new products failure to conform to Foreign Corrupt Practice Act regulations and legal proceedings, risk of expanding into the plans for a CDMO business, uncertainties associated with the COVID-19 epidemic, and other risks that are listed regularly in the Company’s filings with the Securities and Exchange Commission (“SEC”).
ThermoGenesis Returns against. S&P
| 1 YEAR | 5 YEARS | 5 YEAR Annualized | SINCE IPO | |
|---|---|---|---|---|
| THMO | ||||
| S&P | 0% |
Assets
QARTERLYAnnual
| Q3 2022 | YOY MODIFY | |
|---|---|---|
| Net Cash | $3.90M | -48.9% |
| Accounts Receivable | $2.06M | -20.0% |
| Inventory | 4.912 | -11.3% |
Liability
QARTERLYAn Annual
| Q3 2022 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.83M | +741.1% |
| Short Term Debt | $6.53M | -30.1% |
Ratios
QARTERLYAnnual
| Q3 2022 | YOY MODIFY | |
|---|---|---|
| Return On Assets | -49.0% | -15.3% |
| Return On Invested Capital | -158.1% | -10.4% |
Cash Flow
QARTERLYAnnual
| Q3 2022 | YOY MODIFY | |
|---|---|---|
| Free Cash Flow | -$1.09M | +5.3% |
| Operating Free Cash Flow | -$1.00M | -4.8% |
Valuation
QARTERLYAnnual
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY MODIFY | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | 3.14 | 4.74 | 1.24 | 1.53 | -58.6% |
| Price to Sales | 1.29 | 0.80 | 0.33 | 0.76 | -71.4% |
| Price to Tangible Book Value | 127.09 | 210.82 | -632.10 | 75.81 | -57.4% |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | -12.82 | -14.62 | -8.06 | -7.61 | -71.6% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | -236.4% | -176.6% | -126.9% | -183.0% | -24.9% |
| Total Debt | $10.66M | $11.34M | $10.48M | $10.36M | +5.7% |
